Safety outcomes associated with the moderna COVID-19 vaccine (mRNA-1273): a literature review
Introduction Current safety data from Phase 3 clinical trials have concluded that apart from transient local and systemic reactions, no safety concerns were identified for the Moderna COVID-19 vaccine (mRNA-1273). However, Phase 3 studies are insufficient to detect rare adverse events (AEs). A liter...
Main Authors: | Angel Shabu, Prasad S. Nishtala |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-12-01
|
Series: | Expert Review of Vaccines |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/14760584.2023.2209177 |
Similar Items
-
Analysis of the adverse events following the mRNA-1273 COVID-19 vaccine
by: Angel Shabu, et al.
Published: (2023-12-01) -
Myasthenia Gravis Presenting after Administration of the mRNA-1273 Vaccine
by: Yoji Hoshina, et al.
Published: (2022-07-01) -
Association Between Fever and Antibody Titer Trends After a Third Dose of the mRNA-1273 Vaccine
by: Naomi Matsumoto, et al.
Published: (2022-12-01) -
Myocarditis following COVID‐19 mRNA (mRNA‐1273) vaccination
by: Suresh Babu Chellapandian, et al.
Published: (2022-04-01) -
Impact of Moderna mRNA-1273 Booster Vaccine on Fully Vaccinated High-Risk Chronic Dialysis Patients after Loss of Humoral Response
by: Sammy Patyna, et al.
Published: (2022-04-01)